Acute Promyelocytic Leukemia (APL) Treated With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin (NCT01409161)
The goal of this clinical research study is to learn if the combination of all-trans retinoic acid (ATRA), arsenic trioxide (ATO), and the antibody-drug conjugate gemtuzumab ozogamicin (GO) can help to control APL. The safety of this drug combination will also be studied.
- Condition: Leukemia
- Phase: II
- Estimated Enrollment: 100
- Start: October 2011
- Estimated Primary Completion: October 2017
- Last verified: June 2015
Last Editorial review: July 17, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.